BioAge Labs, Inc. (BIOA) fair value analysis
Nasdaq · Updated 2026-10-19
BIOA price how computed
Valuation status
No fair-value estimate yetBIOA has no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for our trailing P/E history.
Forward Fair Value needs both, so TickrTrends publishes no verdict for BIOA yet. We re-check every week; the price, fundamentals, technicals and earnings data below are unaffected.
- Last price
- $4.84
- Sector
- Healthcare
- 12-month range
- $4.84–$25.10
- Market cap
- $222M
- From 52-week high
- -80.7%
- Shares outstanding
- 45.9M
- Rank in Healthcare by quality score
- #180 of 301
Last price is the 2026-10-16 close; the chart runs through 2026-10-16.
BioAge Labs, Inc. is a healthcare company that develops diagnostic tests and therapeutics focused on biological aging and age-related diseases. The company operates in the United States and conducts research and development activities related to extending healthspan and identifying biomarkers of aging.
BIOA currently ranks #180 of 301 Healthcare stocks by quality score.
Fundamentals (4 quarters) how computed
- Market cap
- $222M
- P/E (trailing)
- n/m
- Revenue (TTM)
- $10.4M
- Net margin
- -912.3%
- EPS (TTM)
- $-2.38
- Gross margin
- 100.0%
- Debt / equity
- 0.01
- Shares outstanding
- 45.9M
Derived indicators how computed
- Quality grade
- F
- Margin trend
- Expanding
- 52-week position
- The bottom quarter of its range
Technicals how computed
- RSI (14-day)
- 13 · oversold
- 50-day average
- $8.43
- 200-day average
- $16.33
- Moving-average state
- 50-day below 200-day (death cross state); price below both averages
Earnings how computed
- Next earnings report
- 2026-11-05
- Last 8 quarters vs consensus
- 3 beat, 5 missed
- Quarter by quarter
- 2026-06 ▲ beat (+10.8%)
2026-03 ▲ beat (+26.8%)
2025-12 ▼ miss (-7.7%)
2025-09 ▼ miss (-9.8%)
2025-06 ▼ miss (-57.9%)
2025-03 ▲ beat (+32.1%)
2024-12 ▼ miss (-52.7%)
2024-09 ▼ miss (-817.8%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 7 buy · 2 hold · 0 sell (9 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $32.6
- Target vs last price
- +573.6%
What our data shows for BIOA
- Shares are trading in the lower third of their 12-month price range of $4.84–$25.10.
- The 14-day relative strength index sits at an oversold 13.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- BIOA's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
What people are saying
Follow the BIOA conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.
Frequently asked questions
Is BIOA stock undervalued?
TickrTrends has no fair-value estimate for BIOA yet: there is no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for a trailing P/E history. It is re-checked every week.
What is BIOA's TickrTrends verdict?
BIOA is currently marked 'No fair-value estimate yet' - a verdict publishes automatically once a forward earnings consensus and enough reported quarters are available.
How does BIOA compare to other Healthcare stocks?
BIOA ranks #180 of 301 Healthcare stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.
Is BIOA overbought or oversold?
BIOA's 14-day RSI is in the oversold zone on TickrTrends' latest weekly data.
When does BIOA report earnings next?
BIOA's next earnings report is scheduled for 2026-11-05, per the published earnings calendar.
Does BIOA usually beat earnings estimates?
Over its last 8 reported quarters BIOA beat the consensus estimate 3 times and missed 5 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about BIOA?
Of 9 analysts covering BIOA, 7 rate it a buy, 2 a hold and 0 a sell - buy-leaning, with a consensus price target of $32.6 (+573.6% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.